Page 1605 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 87 Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma 1431

population based study of 1,555 patients diagnosed in Sweden from Stone MJ, Bogen SA: Evidence-based focused review of management of
1980 to 2005. Am J Hematol 88:60, 2013. hyperviscosity syndrome. Blood 119:2205, 2012.
Kyle RA, Treon SP, Alexanian R, et al: Prognostic markers and criteria to Swerdlow SH, Campo E, Harris NL, et al: WHO classification of tumours
initiate therapy in Waldenström’s macroglobulinemia: consensus panel of haematopoietic and lymphoid tissues, ed 4, Lyon, France, 2008, IARC
recommendations from the Second International Workshop on Walden- Press.
ström’s Macroglobulinemia. Semin Oncol 30:116, 2003. Treon SP, Hunter ZR, Aggarwal A, et al: Characterization of familial Walden-
Menke MN, Feke GT, McMeel JW, et al: Hyperviscosity-related retinopathy ström’s macroglobulinemia. Ann Oncol 17:488, 2006.
in Waldenström’s macroglobulinemia. Arch Ophthalmol 124:1601, 2006. Treon SP, Xu L, Yang G, et al: MYD88 L265P somatic mutation in Walden-
Merlini G, Baldini L, Broglia C, et al: Prognostic factors in symptomatic ström’s macroglobulinemia. N Engl J Med 367:826, 2012.
Waldenström’s macroglobulinemia. Semin Oncol 30:211, 2003. Treon SP, Cao Y, Xu L, et al: Somatic mutations in MYD88 and CXCR4 are
Merlini G, Farhangi M, Osserman EF: Monoclonal immunoglobulins with determinants of clinical presentation and overall survival in Waldenström
antibody activity in myeloma, macroglobulinemia and related plasma cell macroglobulinemia. Blood 123:2791, 2014.
dyscrasias. Semin Oncol 13:350, 1986. Treon SP: How I treat Waldenström macroglobulinemia. Blood 126:721,
Morel P, Duhamel A, Gobbi P, et al: International prognostic scoring system 2015.
for Waldenström macroglobulinemia. Blood 113:4163, 2009. Treon SP, Tripsas CK, Meid K, et al: Ibrutinib in previously treated Walden-
Nobile-Orazio E, Marmiroli P, Baldini L, et al: Peripheral neuropathy in ström’s macroglobulinemia. N Engl J Med 372:1430, 2015.
macroglobulinemia: incidence and antigen-specificity of M proteins. Varettoni M, Arcaini L, Zibellini S, et al: Prevalence and clinical significance
Neurology 37:1506, 1987. of the MYD88 L265P somatic mutation in Waldenström macroglobulin-
Nguyen-Khac F, Lambert J, Chapiro E, et al: Chromosomal aberrations emia, and related lymphoid neoplasms. Blood 121:2522, 2013.
and their prognostic value in a series of 174 untreated patients with Xu L, Hunter Z, Yang G, et al: MYD88 L265P in Waldenström macro-
Waldenström’s macroglobulinemia. Haematologica 98:649, 2013. globulinemia, immunoglobulin M monoclonal gammopathy, and other
Owen RG, Treon SP, Al-Katib A, et al: Clinicopathological definition of B-cell lymphoproliferative disorders using conventional and quantitative
Waldenström’s macroglobulinemia: consensus panel recommendations allele-specific polymerase chain reaction. Blood 121:2051, 2013.
from the Second International Workshop on Waldenström’s Macroglobu- Yang G, Zhou Y, Liu X, et al: A mutation in MYD88 (L265P) supports
linemia. Semin Oncol 30:110, 2003. the survival of lymphoplasmacytic cells by activation of Bruton tyrosine
Poulain S, Roumier C, Decambron A, et al: MYD88 L265P mutation in kinase in Waldenström macroglobulinemia. Blood 122:1222, 2013.
Waldenström’s macroglobulinemia. Blood 121:4504, 2013.
Roccaro A, Sacco A, Jiminez C, et al: C1013G/CXCR4 acts as a driver
mutation of tumor progression and modulator of drug resistance in
lymphoplasmacytic lymphoma. Blood 123:4120, 2014.